Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

Exclusion Criteria

• •Clinical signs indicative of COVID-19 illness requiring hospitalization
• •Admitted to a hospital prior to randomization or is hospitalized (inpatient) at randomization due to COVID-19
• •In the opinion of the investigator, is likely to experience imminent deterioration and require hospitalization
• •Treatment with an investigational drug within 5 half-lives or 3 months (whichever is longer) of randomization
• •Treatment with a COVID-19 therapeutic agent including, but not limited to, other direct or indirect acting antivirals against SARS-CoV-2 (such as remdesivir or favipiravir), systemic or inhaled steroids (such as dexamethasone or inhaled budesonide), colchicine, ivermectin, interferons, convalescent plasma, monoclonal antibodies against SARS CoV-2 or interleukin 6 (IL-6), intravenous immunoglobulin or other EUA-approved treatments within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to the screening visit
• •Concomitant use of P-glycoprotein inhibitors or inducers listed as prohibited therapy in the protocol
• •Known allergy or hypersensitivity to components of study drug
• •Abnormal laboratory test results at screening
• •Requirement of any prohibited medications during the study
• •Other known active viral or bacterial infection at the time of screening, such as influenza
• •Any clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, could jeopardize the safety of the patient or affect patient compliance or safety/efficacy observations during the study
• •COVID-19 vaccination within ≤ 40-days prior to enrollment (second dose if applicable)